Cost Recovery Implementation Statement – Administration of the Prescribed List of Medical Devices and Human Tissue Products 2025-26

This CRIS provides information on how the Department of Health, Disability and Ageing (the Department) implements cost recovery charging for:

• applications to the Medical Devices and Human Tissue Advisory Committee (MDHTAC) for medical devices seeking to be listed on the Prescribed List of Medical Devices and Human Tissue Products (the Prescribed List)
• applicant-driven listing and list management activities for the Prescribed List. 

It reports actual financial and non-financial performance information, outlines legislative changes and contains financial and demand forecasts for 2025-2026 and three forward years. The Department will maintain the CRIS while the regulatory activity, or cost recovery for the activity, continues.